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Abstract: Heart valve development is governed by both genetic and biomechanical inputs. Prior
work has demonstrated that oscillating shear stress associated with blood flow is required for normal
atrioventricular (AV) valve development. Cardiac afterload is defined as the pressure the ventricle
must overcome in order to pump blood throughout the circulatory system. In human patients,
conditions of high afterload can cause valve pathology. Whether high afterload adversely affects
embryonic valve development remains poorly understood. Here we describe a zebrafish model
exhibiting increased myocardial afterload, caused by vasopressin, a vasoconstrictive drug. We show
that the application of vasopressin reliably produces an increase in afterload without directly acting
on cardiac tissue in zebrafish embryos. We have found that increased afterload alters the rate of
growth of the cardiac chambers and causes remodeling of cardiomyocytes. Consistent with pathology
seen in patients with clinically high afterload, we see defects in both the form and the function
of the valve leaflets. Our results suggest that valve defects are due to changes in atrioventricular
myocyte signaling, rather than pressure directly acting on the endothelial valve leaflet cells. Cardiac
afterload should therefore be considered a biomechanical factor that particularly impacts embryonic
valve development.
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1. Introduction
Congenital heart defects (CHD) occur when the heart fails to form appropriately during the early stages of embryonic development. Approximately 1.35 million newborns born
annually with CHD worldwide [1]. Valve pathology occurs in over 50% of all CHD cases [2].
Despite the prevalence of CHD, the etiology of CHD is not well understood. In fact, only
approximately 20% of all CHD arise from a known genetic lesion [3]. Phenotypicallysimilar CHD may arise from mutations in unrelated proteins [4], and conversely, identical
mutations can cause a variety of distinct phenotypes [5]. A likely explanation of this
phenomenon is that the pathology arises not only from loss or modification of protein
function, but also through the alteration of the mechanical environment of the heart. Increasingly, research efforts are directed at defining biomechanical contributions to normal
heart development and CHD.
Shear stress produced by blood flow within the heart lumen, contraction itself, and
pressures resulting from contraction, represent types of biomechanical cues that facilitate
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the normal development of the valves [6,7]. Because endothelial cells contributing to
development of the AV valve are in direct contact with blood flow, they may be especially
sensitive to perturbations in hemodynamics. As one example, exposure of porcine valves
to physiological levels of shear stress was found to directly impact the development of the
striated ECM present in the valve leaflets through the induction of collagen expression and
even differentially affects each forming valve leaflet [8].
While the biomechanical signals derived from shear stress are increasingly well characterized, the impact of other potential biomechanical signals, such as cardiac loading on
cardiac development, remain relatively uninvestigated. Afterload refers to the resistance
the ventricle must overcome in order to pump blood throughout the circulatory system.
For a given cardiac output, the pressure is proportional to the flow rate times the resistance.
The higher the afterload, the higher the transmural pressure throughout the heart [9].
In the fetus, conditions of high afterload have been linked to ventricular hypertrophy
and fetal hydrops [10]. Human fetuses with decreased fetal growth demonstrate decreased
cardiac output thought to be caused by increased afterload [11], as well as tricuspid valve
regurgitation [10]. Moreover, afterload is linked to CHD as shown by work demonstrating
that reduction in afterload through hydralazine (a vasodilator) treatment can help to
mitigate large ventricular septal defects [12,13]. The impact of high afterload has been
best characterized in adult organisms, where its deleterious effects lead to valve pathology
and cardiac hypertrophy [14–16]. Specifically, adult patients with conditions of increased
afterload often experience concentric pathologic hypertrophy, in which sarcomeres are
added in parallel within existing myofibrils [17]. A better understanding of the molecular
circuitry activated by the afterload-response may yield translational insights into the causes
of both adult valve pathology and CHD.
Studies of how abnormal afterload might impact embryonic valve development so far
have been hampered by a paucity of in vivo tools able to accurately and reliably induce the
conditions of altered loading without directly impairing cardiac contraction. Prior work
has utilized models such as outflow tract (OFT) ligation in chick embryos to increase afterload [18]. Increasing afterload through OFT ligation has resulted in a smaller mitral valve,
dysregulation of shear-stress-responsive genes and altered expression of ECM markers [19].
Conversely, computational models of avian embryonic valve development have predicted
that increased pressure on the developing endocardial cushions would promote leaflet-like
elongation. These studies demonstrate that loading can affect AV valve development.
In order to respond to changes in afterload, cells at the atrio-ventricular junction (AVJ)
must be able to perceive changes in blood flow and pressure. Endocardial cells can sense
both the direction and the magnitude of blood flow through mechanosensors [7]. The
monocilia present on endocardial cells are thought to bend under conditions of high flow
and shear stress, leading to the activation of signaling pathways. Mouse endocardial cells
lacking cardiac cilia fail to properly develop endocardial cushions and show impaired
endothelial-to-mesenchymal transition (EMT) [20]. Mechanosensitive ion channels can
activate expression of transcription factor klf2a under conditions of oscillatory flow [21].
Despite being physically separated from flow, myocardial cells also play a role in mechanotransduction. In vitro rat myocardial cells adapted to changes in load by undergoing
hypertrophy [15]. Myocardial cells may perceive changes in load by assessing their degree
of stretch using NFAT–calcineurin or titan-mediated mechanisms [22]. These cells may also
sense the direct pressure transmitted through the cardiac wall through integrin-mediated
mechanisms [22]. As part of their normal function, myocardial cells release paracrine
signaling factors, such as BMP, that are required to signal endocardial differentiation [23].
Based on these findings, it is possible that the loading state of the myocytes impacts their
release of key signals required for normal valve development.
In the circulatory system, resistance is mathematically described as Resistance =
(8µL)/(πr4 ); where µ is the fluid viscosity, L is the length of the vessel, and r is the radius of
the vessel. Because of this relationship, very small changes in the radius of the vasculature
can have a dramatic impact on the resistance (and afterload) the heart encounters. We
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therefore chose to use vasopressin, a potent vasoconstrictor, to increase afterload and
evaluate the effects on AV valve development in embryonic zebrafish.
Vasopressin is an amino-acid hormone that causes vasoconstriction. The zebrafish
genome encodes the following three vasopressin receptors: avtr1a1 , avtr1a2 , and avpr2.
Avtr1a1 and avtr1a2 are both homologues of the mammalian V1a receptor [24]. The mammalian V1 receptor is expressed predominantly in the smooth muscle cells surrounding
peripheral vessels. Vasopressin binding triggers an intracellular cascade that increases
the intracellular calcium concentration and consequently causes muscle constriction and
vasoconstriction [25]. The mammalian V2 receptor, which is a homolog of the zebrafish
avpr2 receptor, is expressed predominantly in the kidneys and acts to increase blood volume.
Stimulation via either receptor raises blood pressure and directly increases myocardial
afterload through increased vascular resistance [26].
Here, we show that vasopressin is vasoactive in zebrafish, and demonstrate that
vasopressin application produces alterations in cardiac function and growth. We find that
increased afterload affects the differentiation of both endocardial and myocardial valve cells.
Our data support myocardial AVJ cells as especially sensitive to alterations in afterload in
normal development.
2. Materials and Methods
2.1. Zebrafish Husbandry and Vasopressin Application
Zebrafish were raised as per Colorado State University animal care and use protocols.
Zebrafish embryos were raised at 28.5 ◦ C until 24 hpf in E3 medium, and dechorionated.
Embryos were placed in a solution of arginine vasopressin acetate salt (Sigma, catalog
number V9879, St. Louis, MO, USA) diluted in E3 embryo media to a final concentration
of 10 µmol/L, unless otherwise specified. Treated embryos remained in the vasopressin
solution for the entirety of the study.
2.2. Live Imaging
For vessel and whole-heart live imaging, samples were immobilized in low-melting
agarose. Quantification of vessel diameter was performed in Image J [27]. Quantification of
cardiac chamber volume and looping angle was performed as previously described [28,29].
For live imaging of the valves, confocal microscopy was used. Embryos were treated
with MESAB until cardiac contraction stopped, and then mounted in low-melt agarose in a
depression slide in a tilted ventral-up orientation, such that the heart was roughly parallel
to the coverslip.
2.3. Quantification of Cardiac Functional Parameters
Quantification of cardiac parameters (cardiac output, stroke volume, and heart rate)
was performed as previously described [30]. Briefly, embryos were raised at 28.5 ◦ C until
the appropriate time point. Fish were mounted in low-melt agarose, with no MESAB.
Videos were taken with a Photron Mini UX-100 camera at 1600 frames per second, across at
least 3 cardiac cycles. Videos were analyzed as previously described using a line scan and
spatiotemporal kymographs to quantify cell movement along the line scan [30].
2.4. Immunohistochemistry
Immunohistochemistry was performed on dissected zebrafish hearts as previously
described [31]. Briefly, hearts were dissected in an L15-10% FBS solution and then placed
on a polylysine-coated slide. Hearts were fixed for 40 min in 4% PFA and permeabilized
with a 1% solution of Triton X. For ALCAM labelling, zn8 antibody (Developmental Studies
Hybridoma Bank) was used at 1:10 dilution. Embryos were washed 3xwith PBST solution
and then incubated with Alexa-546 anti-mouse IgG secondary antibody (Thermo Fischer
Cat #A-11030, Eugene, OR, USA) at a 1:200 dilution. Hearts were mounted in 50% glycerol
under coverslips. Images were taken on the Zeiss LSM800 and analyzed blind.
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In order to measure directly whether vasopressin elicits vasoconstriction in zebrafish
embryos, we transferred Tg(fli1:EGFP) embryos at 24 h post-fertilization (hpf) to media
containing 10 µM of vasopressin, and measured vessel diameters at 52 hpf by assessing the
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outside borders of the GFP-labeled endothelial cells (Figure 1B–D). We found that 24 h of
vasopressin exposure was sufficient to cause significant vasoconstriction of the major blood
vessels (18% constriction in the dorsal aorta and 25% constriction in the cardinal vein;
mboxemphp = 0.007 for dorsal aorta, p = 0.0004 for cardinal vein). Vessel radius is the
major regulator of vascular resistance in the body (Resistance = (8µL)/(πr4 ); where µ is
the fluid viscosity, L is the length of the vessel, and r is the radius of the vessel). Thus,
an 18 or 25 percent constriction in diameter corresponds to a 124% and 281% increase
in resistance, respectively, with the assumptions of Hagen–Poiseuille flow. Vasopressin
application did not cause any detectable constriction of the intersegmental vessels (ISVs)
(p = 0.43). In order to determine the minimal length of vasopressin exposure sufficient for
significant vasoconstriction, we treated 24 hpf embryos with vasopressin for shorter periods
and again measured the diameter of the dorsal aorta. The embryos that were exposed to
4 h of vasopressin treatment already showed significant constriction in their dorsal aorta
(Supplemental Figure S1B). In order to determine how the length of vasopressin exposure
induced constriction, we treated 24 hpf embryos with varying concentrations of vasopressin
and then evaluated dorsal aorta diameter at 72 hpf (Supplemental Figure S2C). We found
that treatment with 10 µM vasopressin caused a 50% decrease in dorsal aorta diameter at
72 hpf. The application of increasing concentrations did not produce greater constriction
(data not shown). Among treated and untreated embryos, very few exhibited general
abnormalities such as hemorrhaging, or body patterning defects (<5 out of 78 embryos
scored presented either defect). In order to assess the degree of cell death, 72 hpf embryos
were treated with acridine orange, a vital dye. The vasopressin-treated embryos did
not exhibit significantly more cell death than the buffer-treated controls, suggesting that
vasopressin treatment is not toxic to cells (Supplemental Figure S2A). Together, these
data establish vasopressin exposure as a reliable method to increase afterload in zebrafish
embryos without directly acting on cardiac tissue.
3.2. Increased Afterload Alters Cardiac Function and Growth
We next tested the hypothesis that increased afterload impairs zebrafish embryonic
cardiac function. We exposed embryos to 0, 2.5, 5, 7.5, and 10 µM doses of vasopressin
beginning at 24 hpf. After 16 h of continuous vasopressin exposure (i.e., in 40 hpf embryos),
we found that increasing concentrations of vasopressin produced a dose-dependent effect
on vessel constriction (Supplemental Figure S3), and therefore a dose-dependent effect
on afterload. Doses of 5 µM or higher produced significant vessel constriction. In order
to measure cardiac output, control and vasopressin-treated embryos were recorded by
high-speed video. Kymograph analysis provided a measure of the velocity of red blood
cells, which was then used to calculate flow rate. The parameters of cardiac function were
computed from flow rate as previously described [30].
At 24 hpf, the heart has just formed a linear tube and is beginning to contract, but
circulation is not yet robust. We measured the heart rate of embryos immediately before
exposure to 10 µM vasopressin, and then after 5 min of vasopressin exposure (Supplementary Movie 1). There was no significant difference in heart rate post vasopressin
exposure (Supplementary Figure S2B, p = 0.29, n = three control and three vasopressintreated embryos). No overt change in morphology was noted. Consequently, changes
noted at later time points are likely due to remodeling events and not a consequence of
vasopressin application.
At 40 hpf, the constriction at the AVJ has developed, but endocardial cushion formation
has not yet initiated. The analysis of embryos at this time point revealed that embryos
treated with 5 µM vasopressin produced a 1.85-fold increase in cardiac output, and embryos
treated with the 7.5 µM dose produced a 2.11-fold increase in cardiac output relative to
controls (Figure 2A, p = 0.03 for 5 µM, and p = 0.005 for 7.5 µM). These data clearly suggest
that the hearts are sensing the change in load and are implementing functional responses
to meet physiological need. Given that cardiac output is the product of stroke volume
times heart rate, we investigated whether either of these measures changed. The stroke
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The embryos that were exposed to the 10 µM dose reacted differently than those
exposed to lower doses. First, they did not achieve an increase in cardiac output by
40 hpf, but instead demonstrated a significant decrease in cardiac output (Figure 2C;
control = 50.6 nL/min, vasopressin = 32.26 nL/min, p = 0.04 by t-test, n = 15 control,
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and 23 vasopressin-treated embryos). A subset of the embryos treated with 10 µM vasopressin (7 out of 23 embryos) exhibited disproportionate chambers and increased looping
angle (Supplementary Movie 2). These embryos were termed “severely affected” while
embryos that did not exhibit these overt morphological defects were termed “mildly
affected”. The looping angle was evaluated by measuring the angle between the line
bisecting the atrium and the line parallel to blood flow in the AVJ [30]. The control and
mildly-affected embryos displayed similar looping angles (109◦ for control, 104◦ for mildly
affected; n = 16 control, 16 mildly affected, p = 0.52 by Dunnett’s test), while severelyaffected embryos had an average looping angle of 139◦ (n = 7, p = 0.002 against control by
Dunnett’s test, Supplemental Figure S6A).
In order to evaluate if treated chambers grew in proportion to those in the control
hearts, we measured the cross-sectional area of the ventricle and atrium at the end of
ventricular contraction and calculated the ratio of ventricular area to atrial area. Control and
mildly-affected embryos displayed similar chamber area ratios (control = 0.42, mild = 0.47,
p = 0.25 by Dunnett’s test), whereas the chamber area ratio of severely-affected embryos was
significantly smaller (ratio = 0.27, p = 0.00013 by Dunnett’s test, Supplemental Figure S6B).
In order to further analyze these data, we plotted embryo count against the looping angle or
chamber area ratio (Supplemental Figure S7). In both cases, the severely-affected embryos
clustered together, and the data distributions appeared bimodal (Hartigan’s dip test for
unimodality, p = 0.03 for looping angle, and p = 0.05 for chamber area ratio). Together, these
data indicate that under conditions of high afterload, about two-thirds of hearts develop the
correct chamber morphology and looping angle by 40 hpf, while approximately one-third
of hearts were compromised.
In order to understand how increasing afterload alters overall contraction patterns
in the heart, we measured the speed of the progressing contractile wave in the control
and the 10 µM vasopressin-treated embryos at 40 hpf. In this assay, we tracked successive
points of maximal chamber lumen constriction as contractile wave progressed across the
length of the heart tube. The speed of the contraction wave across the cardiac cycle was
plotted against normalized time; where 0 corresponds to the onset of contraction at the
atrial inlet, and one corresponds to the completion of ventricular systole. In the control
embryos, the speed of contraction during atrial systole peaked at 2.4 mm/s, then slowed to
0.3 mm/s as the wave passed into the AVJ, followed by increases in speed as contraction
proceeded through the ventricle (Supplemental Figure S8). In the 10 µM vasopressintreated group, both mild embryos and severe embryos displayed similar contraction wave
patterns: contraction through at the atrial inlet began with a similar speed (control average:
2.2 mm/s, vasopressin average: 2.5 mm/s, p = 0.30), but the speed did not peak near the
end of atrial systole as occurred in the control embryos. Furthermore, the speed of the
contraction wave in the AVJ itself was two to three-fold higher in both the mild and the
severe vasopressin-treated embryos, a significant difference (Supplemental Figure S9A,
n = 11 control, 15 mild, and 7 severe vasopressin-treated embryos; p = 0.03 for control
vs. mild, and p = 0.003 for control vs. severe by Dunnett’s test). In order to correct for
possible variability in the overall contraction speed in each heart, we normalized the AVJ
speed to the maximum speed in each heart, but significant increases were still detectable
(Supplemental Figure S9B). Together these data indicate that increased afterload has already
altered cardiac contraction patterns by 40 hpf and specifically alters AVJ function, even in
the mildly-affected group.
In order to investigate how increasing afterload alters embryonic pumping mechanics,
we evaluated the length of endothelial closure in 40 hpf embryos. During each cardiac
cycle, there exists a period during which the endothelial layers lining either side of the
AVJ come into brief physical contact. In the control embryos, the length of endothelial
closure (i.e., the extent of maximal endothelial contact in the AVJ region) approximates
77 µm at the end of ventricular systole (see Supplemental Figure S10). Previously, our
group identified the length of endothelial closure as a parameter that embryonic hearts can
alter to adapt to increases in pressure and limit reverse flow [32]. Thus, we hypothesized
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that as afterload increased in relation to greater vasopressin concentrations, the length of
endothelial closure would also increase. We measured the length of endothelial closure
for each dose of vasopressin (from 0 to 10 µM). As predicted, vasopressin elicited a doseresponsive increase in the length of endothelial closure by 40 hpf (Supplemental Figure S10).
These data suggest that hearts which are subjected to sustained high afterload use increased
endothelial closure as one means to adapt to stressful pr.essure.
By 56 hpf, the chambers have undergone primary ballooning and endocardial cushion
development is robust. After 32 h of continuous vasopressin exposure (i.e., in 56 hpf
embryos), we re-examined heart function to determine how well hearts had adapted to
a period of sustained high afterload. Remarkably, by 56 hpf no significant differences
in cardiac output were detected at any of the doses tested except for the 10 µM, which
displayed significantly increased cardiac output (Figure 2C, p = 0.04 by Tukey’s). No
embryos overtly exhibited weakened contractility. Since these findings contrasted with
those of 40 hpf, we hypothesized that embryo hearts have adapted to rescue cardiac
function by 56 hpf. In order to test this hypothesis, we tracked the individual control or
10 µM vasopressin-treated embryos and assessed cardiac function at both 40 and 56 hpf.
We obtained time-matched data sets for four control and eight vasopressin-treated embryos,
of which two had exhibited the severe phenotype at 40 hpf. Intriguingly, these two embryos
did not display any overt morphological defects at 56 hpf (Supplementary Movie 3). The
control embryos uniformly increased cardiac output between 40 and 56 hpf (n = 4), while
the vasopressin-treated embryos exhibited much more variability in their response (n = 8;
Figure 2C). The quantification of the rate of change using Bartlett’s test for homogeneity of
variance confirmed that vasopressin-treated embryos responded with significantly more
variability than the controls (Figure 2D; p = 0.01), though their overall rate of change was
not significantly different (p = 0.27). These data indicate that at the highest tested condition
of afterload, rather than continuing the downward trend in function seen at 40 hpf, embryos
were on average able to sustain their CO by 56 hpf, and in some cases increase it over
the controls.
To better understand how the embryos at the 10 µM dose had modulated cardiac
output, we analyzed stroke volume and heart rate at 56 hpf. No significant differences were
detected in stroke volume at 40 hpf (p = 0.32 by Kruskal-Wallis). However, at 56 hpf, stroke
volume was ~50% higher in the vasopressin-treated embryos compared to the controls, a
significant change (Figure 2E, p = 0.04 by t-test). At 40 hpf, the vasopressin-treated embryos
had demonstrated heart rates approximately 7% higher than the controls, a significant
change (Figure 2F, p = 0.03 by t-test), but heart rates at 56 hpf matched the controls. These
data suggest that increased heart rate was the initial adaptation to compensate for increased
afterload at 40 hpf, but that increased stroke volume was the primary driving force that
maintained (or increased) cardiac output at 56 hpf.
3.3. Increased Afterload Induces Cardiac Hypertrophy and Alters Sarcomere Abundance
Compared to the lower doses, the 10 µM treated embryos took longer to ramp up their
response of increased cardiac output, as might be expected by the work needed for hearts
to pump against such high resistance. We hypothesized that the hearts in 56 hpf treated
embryos had structurally remodeled to provide a sustainable response. The next series of
experiments focused on the 10 µM treated embryos in order to investigate this hypothesis.
Murine models indicate that hypertrophy in the cardiac ventricle reflects an increase in
myocardial cell size, while embryonic chicks undergo hyperplasia in response to conotruncal banding [33,34]. In order to evaluate whether or not zebrafish experience hyperplasia
in response to increases in afterload, we exposed the Tg(myl:dsred-nuc) embryos, which
express dsRED in the nucleus of cardiomyocytes, to 10 µM vasopressin from 24 to 56 hpf
and evaluated the ventricular cell number. We found no change in the number of ventricular cardiomyocytes between the control and the vasopressin-treated embryos (control
average = 82, vasopressin average = 87, p = 0.48, n = four control and five vasopressintreated embryos, Supplementary Figure S11). In order to evaluate ventricle size in zebrafish,
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the Tg(myl7:eGFP) embryos, which express GFP in cardiomyocytes [35], were treated with
10 µM vasopressin from 24–56 hpf. The vasopressin-treated hearts showed a significant
increase in overall ventricular volume (Supplemental Figure S12). In order to further
determine if increases in loading increased the myocardial cell size or shape, we evaluated
cardiomyocytes using rhodamine-labeled phalloidin, which binds actin fibers located predominantly near the cell periphery. By 52 hpf, myocardial cells in the mid-ventricle were
17% larger in the vasopressin-treated hearts relative to the controls (p = 0.04), but retained a
similar degree of circularity (Supplemental Figure S12; p = 0.23). Thus, application of vasopressin to zebrafish embryos recapitulates the hypertrophic effects of afterload observed in
other vertebrate animal models.
Because embryos exposed to the 10 µM dose of vasopressin experienced an increase in
stroke volume, we hypothesized that they may increase their myofibril content on a per-cell
basis. Following the approach of Lin et al. (2012), we used the Tg(myl7:cypher-eGFP)
transgenic line to visualize z-bands in the heart, and quantify their size and number per
cell [36]. The summed length of all z-bands represents the total z-band size (TZB) per cell
(Supplemental Figure S13. The TZB is normalized to the planar cross-sectional area of the
cell to assess the total myofibril content per cell while accounting for differences in cell size.
In order to determine whether increased myofibril content could account for the increase in stroke volume observed in embryos treated with the 10 µM dose of vasopressin at
56 hpf, we measured myofibril content of individual ventricular outer curvature cardiomyocytes using the Tg(myl7:cypher-eGFP) line, in which cypher (a z-disc protein) has been
tagged with eGFP (Figure 3). We performed immunohistochemistry using the ALCAM
(activated leukocyte cell adhesion molecule; also called DM-GRASP) antibody, which marks
myocardial cell borders to measure the cross-sectional area of each ALCAM-labeled cell
(Figure 3A,B000 ). We observed that cells exposed to 10 µM vasopressin were approximately
10% larger than their untreated counterparts (p = 0.04) (Figure 3C), consistent with the
rhodamine-phalloidin data above. After being normalized to the individual cell area,
the data indicated an approximately 5% average increase in TZB in vasopressin-treated
cardiomyocytes beyond what was expected by the cells’ larger size (p = 0.03) (Figure 3D).
Further experiments were conducted to determine whether the z-band number (a rubric for
the number of sarcomeres present) or average z-band size (reflecting the thickness of the
sarcomere) accounted for the increased TZB. We found the number of z-bands per cell was
significantly increased from 25.3 z-bands/cell in the control embryos to 32.4 z-bands/cell
in the vasopressin-treated embryos (p < 0.001) (Figure 3E), suggesting that treated cells
increased their myofibril content. However, the average length of individual z-bands was
not significantly affected (p = 0.24) (Figure 3E), suggesting that myofibril thickness was not
changed. This pattern of increased number of sarcomeres is consistent with pathological
concentric hypertrophy.
3.4. Increased Afterload Induces Retrograde Flow and Alters AVJ Mechanics
In order to evaluate the valve formation and function, we measured how the diameter
of the AVJ varied across the cardiac cycle in the hearts of live embryos. The hearts of
the vasopressin-treated embryos were scored initially as either ‘mild’ or ‘severe’ based
on their appearance at 40 hpf, and then videoed at 56 hpf. We noted that the dynamics
of AVJ behavior during the cardiac cycle were significantly altered under conditions of
increased loading (Figure 4). The AVJ of the control embryos displayed uniform behavior,
opening with an average maximal diameter of 34.7 µm (Figure 4A,D). The vasopressintreated embryos initially scored as ‘mild’ showed significantly increased average maximal
diameter of 44.5 µm by 56 hpf (p = 0.015 by t-test) (Figure 4B,D). The vasopressin-treated
embryos initially scored as ‘severe’ at 40 hpf displayed reduced average maximal diameters
of 27.7 µm by 56 hpf (p = 0.10 by t-test) (Figure 4C,D). Moreover, AVJs in the vasopressintreated hearts open significantly earlier than the control counterparts (controls at 40%
all vasopressin-exposed embryos at 11%, p = 0.04). Both groups of vasopressin-treated
embryos displayed an increased retrograde flow fraction (RFF), quantified as follows:
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RT

RT
| Qreverse |dt/ 0 | Qtotal |dt, where Q is the flow rate and T is the cardiac cycle period [32].
In the vasopressin-treated embryos, RFF increased approximately three-fold over controls
by 56 hpf (Figure 4E, p = 0.01). Together, these data demonstrate that despite the ability of
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3.5. Increased Afterload Alters Myocardial AVJ Cell Specification
Given that AVJ functional dynamics were altered in conditions of increased afterload,
we next explored whether differentiation of AVJ myocardial, and/or endocardial cells, were
affected in conditions of high afterload. Focusing first on myocardial differentiation specifically at the AVJ, we evaluated the cellular morphology based on ALCAM immunostaining.
By 48 hpf, wildtype AVJ myocytes have acquired a distinct trapezoidal cell morphology,
express Tbx2b, and direct endocardial cell specification via Bmp signaling [23,37]. In
the vasopressin-treated embryos at 56 hpf, AVJ myocytes were on average more circular
than their control counterparts (Supplemental Figure S14A, p = 0.03), suggesting that AVJ
myocytes had not fully differentiated. In contrast to the ventricular outer curvature myocytes, which enlarge (Figure 3), the AVJ myocytes spanned approximately the same area in
vasopressin-treated hearts as in the controls, suggesting that AVJ myocytes do not become
hypertrophic (Supplemental Figure S14B p = 0.62). Upon assessing the total myofibril
content, we observed a 22% decrease in normalized TZB in the vasopressin-treated AVJ
myocytes (Figure 5C, n = 11 control, 10 vasopressin-treated hearts, p = 0.003).
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Figure 5. Increased pressure alters AVJ myocyte morphology and specification. (A) Control and
(B) vaso-treated hearts showing z-disks and cell shape through ALCAM immunohistochemistry at 56
hpf. Purple box shows region of interest shown in (A0 ,B0 ). For (A,B), scale bar represents 20 µm. (A0 )
Control and (B0 ) vaso-treated hearts. Scale bar represents 10 µm. White arrow heads indicate AVJ.
(C) TZB
of sarcomeres
present
eachmyocyte
cell normalized
to theand
areaspecification.
of each cell (1/µm).
n = 36
cells
Figure
5. Increased
pressure
altersinAVJ
morphology
(A) Control
and
(B)for
control
and
33
for
vaso-treated
hearts.
(D)
In
situ
hybridization
(ISH)
of
myocardial
AVJ
marker
vaso-treated hearts showing z-disks and cell shape through ALCAM immunohistochemistry atbmp4
56
hpf.
region of interest
A′ and B′.ofFor
scale bar
represents
20 µm. of
inPurple
controlbox
andshows
(E,F) vaso-treated
hearts.shown
(D0 –F0 in
) Diagrams
ISHA,B,
expression
patterns.
(G) Percent
(A′)fish
Control
and (B′)
vaso-treated
hearts.
Scale bar
represents
10ofµm.
White
arrow
heads
indicate
expressing
a particular
bmp4
expression
pattern.
A total
20 fish
were
scored
in each
group.
AVJ.
(C)
TZB
of
sarcomeres
present
in
each
cell
normalized
to
the
area
of
each
cell
(1/µm).
n = 36
* indicates p < 0.05.
cells for control and 33 for vaso-treated hearts. (D) In situ hybridization (ISH) of myocardial AVJ
marker bmp4
control
and (E,F)
vaso-treated hearts.
(D′–F′)
Diagrams
of ISH
patterns.
Next,inwe
assessed
the specification
of AVJ
myocytes
via in
situ expression
hybridization
using
(G)bmp4
Percent
of
fish
expressing
a
particular
bmp4
expression
pattern.
A
total
of
20
fish
were
and tbx2b probes [38]. In normal hearts, myocardial bmp4 and tbx2b are scored
broadly
in each group. * indicates p < 0.05.

expressed in the ventricle at 33–36 hpf. During the second day of development, the
wildtype hearts gradually down-regulate expression of these markers in the chambers
Next, we assessed the specification of AVJ myocytes via in situ hybridization using
while enriching them at the AVJ, such that AVJ-specific enrichment is evident by 52 hpf [39].
bmp4
and tbx2b
probes
[38]. to
In retract
normaltohearts,
myocardial
bmp4
and tbx2b
broadly exFailure
of these
markers
the AVJ
is observed
in mutant
orare
pharmacological
pressed
in
the
ventricle
at
33–36
hpf.
During
the
second
day
of
development,
the
conditions associated with abnormal valve development [38]. In approximatelywildtype
68% of the
hearts
gradually
down-regulate
expression
of
these
markers
in
the
chambers
while
envasopressin-treated hearts at 56 hpf, bmp4 expression failed to retract to the AVJ and instead
riching
them
at
the
AVJ,
such
that
AVJ-specific
enrichment
is
evident
by
52
hpf
[39].
Failremained broadly expressed in the ventricle or diffusely expressed throughout the heart
ure(Figure
of these
markers
to retract
the AVJ iswas
observed
in mutant
orby
pharmacological
con5G).
In contrast,
tbx2btoexpression
not notably
altered
vasopressin-treatment
ditions
associated
with
abnormal
valve
development
[38].
In
approximately
68%
of
(fold change = 1.10, p = 0.42 by qPCR on dissected hearts). Taken together, thesethe
data
demonstrate that cardiac afterload produces a biomechanical stress that precludes normal
cell differentiation of myocardial cells in the AVJ.

J. Cardiovasc. Dev. Dis. 2022, 9, 22

13 of 18

3.6. Increased Afterload Alters Endocardial AVJ Cell Specification
During valve development in mammals, endocardial cells undergo EMT, invade the
endocardial cushions and become specified valve cells [40]. Although controversy exists
regarding whether true EMT occurs in the AVJ of zebrafish [41,42], AVJ endocardial cells
transition to a more cuboidal shape by 48 hpf, and endocardial cells from the superior
valve leaflet fold into the cardiac jelly around 60 hpf. ALCAM is a well-characterized
marker that appears at the cell periphery from 52 hpf onward only in AVJ endocardial cells
that have become specified to a valve cell fate [43] (in contrast, myocardial cells express
ALCAM throughout development). In order to evaluate endocardial AVJ development,
we performed immunohistochemistry on the dissected wildtype and vasopressin-treated
hearts at 56 hpf to detect ALCAM. Since these hearts were derived from Tg(fli1:eGFP)
embryos, this method labels myocardial cells (red), chamber endocardial cells (green), and
nascent valve endocardial cells in the AVJ (double-labeled red and green) (Figure 6A,B’). The
results indicated a 45% reduction in the number of double-labeled ALCAM-positive valveforming endocardial cells in the vasopressin-treated embryos (Figure 6C, p = 0.000019).
In order to test whether AVJ formation was simply delayed in the vasopressin-treated
embryos, we repeated the same experiment at 72 hpf. We again noted a significant reduction
(approximately 30% fewer) in the number of ALCAM positive endocardial cells in the
vasopressin-treated embryos (n = 12 control, 11 vasopressin treated; p = 0.004). These data
suggest that aberrant loading perturbs AVJ development by limiting the 15
number
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4. Discussion
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of ALCAM expressing endocardial cells. N = 11 wildtype hearts, 10 vaso-treated hearts at 72 hpf.
Five cells were analyzed per location per heart, area was measured for each cell and averaged. AVJ
myocardial cells were defined as myocardial cells located in the constriction between the atrium and
ventricle.

4. Discussion
Here we present vasopressin-treated zebrafish as a novel in vivo model suitable for the
study of the impact of increased myocardial afterload upon the forming heart. Vasopressin
treatment in embryonic zebrafish induces blood vessel constriction, leading to an altered
biomechanical condition consistent with increased afterload. We found that high afterload
produced a pathological cardiac phenotype, and that the hearts subjected to different
vasopressin doses appeared to adapt in different ways. Specifically, the embryos treated
with moderate doses of vasopressin (corresponding to moderate increases in afterload)
responded by increasing cardiac output at 40 hpf, a change which allowed them to continue
to function adequately at 56 hpf. The embryos treated with a high dose of vasopressin
(corresponding to a higher increase in afterload) could not increase cardiac output, but
were able to maintain it, initially by increasing heart rate (at 40 hpf) and later by increasing
stroke volume (at 56 hpf). The hearts in roughly one-third of these high-dose embryos were
clearly compromised at 40 hpf and failing at 56 hpf. However, the hearts in two-thirds
of the high-dose embryos produced adaptive responses that augmented their ability to
continue to function with a normal cardiac output at 56 hpf. Even in these hearts, cardiac
pathology is evident by weaker contractility, slower contractile wave speeds, and increased
variability in cardiac output. Evidence of putative adaptive responses include an expanded
length of endothelial closure within individual heartbeats, induction of hypertrophy via
increased cell size and myofibril content and increased cardiac output by altering heart
rate or stroke volume. Within the AVJ, the negative impact of high afterload is evident by
the disrupted AVJ differentiation and the increased fraction of retrograde flow. Though
application of vasopressin produced variable responses, all treated hearts exhibited signs
of pathology by 56 hpf. Given that the embryonic heart does not express vasopressin
receptors itself, we conclude that vasopressin indirectly produces a high afterload, by
altering the biomechanical environment, and that these changes are pathological for normal
cardiac development.
Prior studies using out-flow tract ligation to alter afterload in the chick embryos
provided initial evidence to suggest that biomechanical signals derived from afterload
impact function in the embryonic heart [6]. Limitations of this model include the requirement for time-consuming surgical manipulations and the limited amenability to genetic
manipulation. The zebrafish vasopressin model complements and extends the chick ligation approach. The ease of vasopressin application enables high-throughput analysis of
phenotypes and enables investigation of the timing and severity of responses to different
doses. The existence of numerous characterized mutant lines in zebrafish offers the further
potential to assess the impact of afterload under various genetic backgrounds. In order to
thoroughly understand the molecular circuitry underlying the afterload-response, it will be
necessary to couple manipulations in loading with manipulations in genetics.
This report provides the first detailed investigation of the functional, cellular, and
molecular consequences of increasing afterload in the embryonic zebrafish heart. The
zebrafish embryonic heart does not express vasopressin receptors, making it unlikely that
vasopressin exerts any direct effects on cardiac contractility. Upon vasopressin treatment,
vasoconstriction is detected in multiple vessels after as little as 4 h of exposure. The degree
of constriction produced by 10 µM is calculated to generate at least a 124% increase in
vascular resistance of the dorsal aorta, thus generating a robust increase in cardiac afterload.
Increasing the load on the embryonic heart during early development (linear heart tube
stage and beyond) dramatically altered cardiac function. In zebrafish, the heart rate of the
10 µM vasopressin-treated embryos increased initially at 40 hpf, but the increase was not
maintained at 56 hpf. In contrast, stroke volume initially matched the controls at 40 hpf,
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but by 56 hpf had significantly increased. Concomitantly, all of the embryos exposed to
10 µM vasopressin showed a significant increase in myofibril content by 56 hpf. These
data suggest that upon exposure to high afterload, embryos initially respond by increasing
their heart rate, perhaps as a temporary compensatory measure. However, upon chronic
exposure to high afterload, embryonic hearts remodel to meet the physiological demands.
More specifically, high afterload produced hypertrophy of the ventricular OC cardiomyocytes by 56 hpf by mechanisms that increased ventricular cell size and increased
myofibril content. This finding is consistent with studies of cultured human embryonic
myocardial stem cells that displayed hypertrophy as well as increased proliferation when
grown in conditions of high afterload [44]. Of note, high afterload in human adults can
also lead to myocardial hypertrophy, reflecting increased ventricular cell size and increased
myofibril content [45,46]. In contrast, chick embryos did not display cardiomyocyte hypertrophy under conditions of high load, but instead showed evidence of cardiomyocyte
hyperplasia [34]. Which mechanotransductive mechanisms facilitate these changes remains an open question but may include disrupted endocardial-ECM-myocardial signaling,
pressure-sensitive receptors, or flow-triggered endocardial responses then communicated
to the myocardium. This finding suggests that high afterload either perturbs communication between the endocardium and the myocardium or generates biomechanical signals
other than RFF and shear stress that impact cardiac hypertrophy.
Strikingly, retrograde flow was significantly increased by 56 hpf in the vasopressintreated embryos. Retrograde flow normally occurs in embryonic hearts aged ~36–72 hpf
for a limited period of each heartbeat [30,32]. The movement of blood cells or plasma
against the endocardial cells within the AVJ generates wall shear stress. Imaging studies
have uncovered a required contribution of shear-stress related biomechanical forces for
regulating normal cardiac valve development [42,47,48]. Vermot and colleagues established
that retrograde flow (i.e., “reversing flows”) constitutes a unique physical stimulus for
valve development, and showed that loss of RFF produced defects in endocardial cushion
formation [47]. Moreover, the complex oscillatory flow patterns present in the AVJ prior
to valve formation create shear-stress patterns that trigger endocardial cells to converge
into the endocardial cushions [49]. In our case, increased RFF did not alter the number
of EC converged at the AVJ by 56 hpf (Supplemental Figure S15), but we did observe
that fewer of those ECs expressed the valve-specification marker, ALCAM (Figure 6).
It is intriguing to speculate that distinct mechanosensitive mechanisms may regulate
endocardial convergence in the AVJ and valve-cell differentiation. Of note, high afterload
has the potential to impact the heart prior to the onset of detectable RFF (~36 hpf), and
therefore may elicit defects independently of complex flow patterns [32,47].
The cellular mechanisms leading to reduced specification of endocardial AVJ cells
remain unresolved. The myocardial cells at the AVJ secrete paracrine factors that promote
endocardial valve cell specification. We speculate that an increase in loading during the
vulnerable valve-formation period may interfere with the appropriate targeted secretion
of key signaling factors by AV myocardial cells. Alternatively, inadequate reception of
these signals by endocardial receptors may lead to fewer specified endocardial valve cells.
Indeed, expression of the myocardial marker bmp4 failed to become restricted to the AVJ by
56 hpf in the vasopressin-treated embryos, suggesting that myocardial AVJ cell specification
is compromised in the vasopressin-treated embryos. In the myocardium, Bmp induces
transcription factors critical for continued myocardial AVJ development, whereas in the
endocardium, the Bmp–Wnt signaling axis promotes AVJ endocardial specification [50,51].
Thus, disruptions in Bmp signaling may be expected to perturb development in both
myocardium and endocardium.
Taken together, our AVJ data show that under conditions of high afterload, the AVJ
myocardial cells fail to develop the myofibillar content expected for their developmental
stage, fail to appropriately transition to the trapezoidal shape expected for differentiating
AVJ myocardial cells, and fail to display the AVJ enriched pattern of myocardial markers
indicative of maturing AVJ. We postulate that these defects in AVJ myocardial cell dif-
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ferentiation interfere with the normal communication between the endocardium and the
myocardium and contribute to a valve defect.
Many open questions remain regarding the mechanobiological means by which afterload elicits the pathological effects shown in this study. Firstly, are some of the high
afterload-associated phenotypes mediated via alterations in shear stress or oscillatory flows,
whereas others are mediated via mechonotransductive cues related to pressure? Prior work
in chick models of high afterload suggest that high load can induce shear-responsive genes
and dysregulation of the ECM. Similar mechanisms may be at play in vasopressin-treated
embryos [19]. Secondly, how are afterload-mediated mechanical signals transduced into
genetic signals? One intriguing hypothesis relates to the cell-stress response. Increased
afterload increases ventricular wall stress. In vivo experiments using coronary artery ligation in adult rat models show that increasing wall stress causes remodeling of the t-tubule
network and disrupts calcium homeostasis [52]. Interestingly, calcium transients have to
been shown to regulate to Bmp signaling during Drosophila melanogaster neural development [53]. It is possible that increasing afterload alters calcium homeostasis during cardiac
development, leading to altered Bmp signaling. More work needs to be done to investigate
this hypothesis, as well as other potential cellular mechanisms for sensing and responding
to afterload.
5. Conclusions
Congenital valve defects arise from aberrations in valve formation during fetal development and frequently cause infant mortality. Surgery, often the only treatment available,
has a ~28% mortality rate. Despite the high clinical burden, more work needs to be done to
understand the underlying molecular and genetic causes of these defects. Here, we present
a zebrafish model wherein high afterload is able to induce a valve development defect and
postulate that afterload acts as a biomechanical cue that cells read and respond to in order
to mediate valve development.
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